CA3126279A1 - Methodes de traitement du cancer du sein avec du tucatinib - Google Patents

Methodes de traitement du cancer du sein avec du tucatinib Download PDF

Info

Publication number
CA3126279A1
CA3126279A1 CA3126279A CA3126279A CA3126279A1 CA 3126279 A1 CA3126279 A1 CA 3126279A1 CA 3126279 A CA3126279 A CA 3126279A CA 3126279 A CA3126279 A CA 3126279A CA 3126279 A1 CA3126279 A1 CA 3126279A1
Authority
CA
Canada
Prior art keywords
subject
months
protein
tucatinib
cytochrome
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3126279A
Other languages
English (en)
Inventor
Luke Walker
Christopher J. Endres
Anthony Jaeyong Lee
Hao Sun
Ariel R. Topletz-Erickson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Seagen Inc
Original Assignee
Seagen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seagen Inc filed Critical Seagen Inc
Publication of CA3126279A1 publication Critical patent/CA3126279A1/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention concerne du tucatinib et son utilisation dans des méthodes de traitement du cancer, tel que le cancer du sein. L'invention concerne également des compositions et des kits comprenant du tucatinib destinés à être utilisés dans le traitement du cancer, tel que le cancer du sein.
CA3126279A 2019-01-28 2020-01-24 Methodes de traitement du cancer du sein avec du tucatinib Pending CA3126279A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962797854P 2019-01-28 2019-01-28
US62/797,854 2019-01-28
PCT/US2020/014953 WO2020159822A1 (fr) 2019-01-28 2020-01-24 Méthodes de traitement du cancer du sein avec du tucatinib

Publications (1)

Publication Number Publication Date
CA3126279A1 true CA3126279A1 (fr) 2020-08-06

Family

ID=69740562

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3126279A Pending CA3126279A1 (fr) 2019-01-28 2020-01-24 Methodes de traitement du cancer du sein avec du tucatinib

Country Status (13)

Country Link
US (1) US20220193076A1 (fr)
EP (1) EP3917533A1 (fr)
JP (1) JP2022523045A (fr)
KR (1) KR20210119498A (fr)
CN (1) CN113613656A (fr)
AR (1) AR119681A1 (fr)
AU (1) AU2020215551A1 (fr)
CA (1) CA3126279A1 (fr)
IL (1) IL284850A (fr)
MX (1) MX2021008834A (fr)
SG (1) SG11202107488PA (fr)
TW (1) TW202042820A (fr)
WO (1) WO2020159822A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201992573A1 (ru) 2017-04-28 2020-04-06 Сиэтл Дженетикс, Инк. Лечение her2-положительных злокачественных новообразований
US20220125877A1 (en) * 2019-07-10 2022-04-28 Sun Yat-Sen University Method for treating colorectal cancer
EP4217400A1 (fr) * 2020-09-28 2023-08-02 Seagen Inc. Procédés de traitement de tumeurs solides ayant des altérations de her2 avec du tucatinib en combinaison avec un anticorps anti-her2
US12036286B2 (en) 2021-03-18 2024-07-16 Seagen Inc. Selective drug release from internalized conjugates of biologically active compounds
WO2024078628A1 (fr) * 2022-10-13 2024-04-18 山东大学 Procédé et composition pharmaceutique de traitement de l'ostéoporose

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4957735A (en) 1984-06-12 1990-09-18 The University Of Tennessee Research Corporation Target-sensitive immunoliposomes- preparation and characterization
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4902505A (en) 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5004697A (en) 1987-08-17 1991-04-02 Univ. Of Ca Cationized antibodies for delivery through the blood-brain barrier
US5055303A (en) 1989-01-31 1991-10-08 Kv Pharmaceutical Company Solid controlled release bioadherent emulsions
US5271961A (en) 1989-11-06 1993-12-21 Alkermes Controlled Therapeutics, Inc. Method for producing protein microspheres
US5188837A (en) 1989-11-13 1993-02-23 Nova Pharmaceutical Corporation Lipsopheres for controlled delivery of substances
US5268164A (en) 1990-04-23 1993-12-07 Alkermes, Inc. Increasing blood-brain barrier permeability with permeabilizer peptides
US5254342A (en) 1991-09-30 1993-10-19 University Of Southern California Compositions and methods for enhanced transepithelial and transendothelial transport or active agents
EP0630234B1 (fr) 1992-03-12 1997-06-11 Alkermes Controlled Therapeutics, Inc. Microspheres a liberation regulee contenant l'hormone adrenocorticotrope (acth)
US5534496A (en) 1992-07-07 1996-07-09 University Of Southern California Methods and compositions to enhance epithelial drug transport
US5514670A (en) 1993-08-13 1996-05-07 Pharmos Corporation Submicron emulsions for delivery of peptides
EA201992573A1 (ru) * 2017-04-28 2020-04-06 Сиэтл Дженетикс, Инк. Лечение her2-положительных злокачественных новообразований

Also Published As

Publication number Publication date
AR119681A1 (es) 2022-01-05
MX2021008834A (es) 2021-09-28
IL284850A (en) 2021-08-31
CN113613656A (zh) 2021-11-05
EP3917533A1 (fr) 2021-12-08
WO2020159822A1 (fr) 2020-08-06
TW202042820A (zh) 2020-12-01
SG11202107488PA (en) 2021-08-30
KR20210119498A (ko) 2021-10-05
JP2022523045A (ja) 2022-04-21
AU2020215551A1 (en) 2021-08-05
US20220193076A1 (en) 2022-06-23

Similar Documents

Publication Publication Date Title
US20220193076A1 (en) Methods of treating breast cancer with tucatinib
US12048698B2 (en) Treatment of HER2 positive cancers
US9421208B2 (en) Methods for the treatment of solid tumors
JP6728072B2 (ja) ｍｄｍ２阻害剤の間欠投与
US20220249528A1 (en) Azacitidine in combination with venetoclax, gilteritinib, midostaurin or other compounds for treating leukemia or myelodysplastic syndrome
CA2817564A1 (fr) Preselection de patients pour un traitement therapeutique fonde sur un etat hypoxique
JP6860949B2 (ja) 癌の処置方法
JP2008501006A (ja) Ｓｒｃキナーゼ阻害剤ＡＺＤ０５３０、および、抗エストロゲン剤またはＥＧＦＲ−ＴＫ−阻害剤を含む組み合わせ製品
WO2012111790A1 (fr) Potentialisateur de l'activité antitumorale d'un agent chimiothérapique
KR20210106484A (ko) Hdm2-p53 상호작용 억제제와 bcl2 억제제의 조합 및 암 치료를 위한 이의 용도
JP2022553041A (ja) Ｈｅｒ２陽性乳がんをカペシタビンおよびトラスツズマブと併用してツカチニブで治療する方法
KR20220125323A (ko) Ahr 억제제 및 이의 용도
CN113939297A (zh) 用于治疗Notch活化的乳腺癌的双氟烷基-1,4-苯并二氮杂卓酮化合物
JP2022527702A (ja) 小細胞肺がんの治療におけるキアウラニブの使用
WO2009052379A2 (fr) Traitements antitumoraux améliorés
TW201036613A (en) Method for predicting therapeutic efficacy of chemotherapy on non-small-cell lung cancer
US20230321102A1 (en) TREATMENT OF CANCER USING COMBINATION THERAPIES COMPRISING GDC-6036 and GDC-0077
WO2023230429A1 (fr) Méthodes de traitement du cancer colorectal avec du tucatinib en combinaison avec un anticorps anti-her2
EA044960B1 (ru) Лечение her2-положительных злокачественных новообразований
Schilder et al. An Open-Label Study to Determine the Maximum Tolerated Dose of Oral ESK-440 Administered as a Single Agent in Patients with Advanced or Metastatic Solid Tumors
JP2016518400A (ja) 頭頚部がんの処置または予防において使用されるｐｉ３キナーゼ阻害剤とパクリタキセルの組合せ

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220921

EEER Examination request

Effective date: 20220921

EEER Examination request

Effective date: 20220921

EEER Examination request

Effective date: 20220921